Alterations in the gut microbiota may drive binge eating, mice study suggests

The findings of a recent study suggest that the interplay between the microbiota, the gut and the brain drives binge-eating disorders.

Direct microbiology – the gateway to reality

Mapping microbial reality by indirect or direct methods? Vermicon AG's position.

Freya Biosciences Secures $38 Million for Pioneering Women’s Reproductive Health Treatments

The investment signals a significant advancement in developing innovative treatments for women's reproductive health issues.

Ferring Pharmaceuticals and PharmaBiome forge groundbreaking microbiome R&D and licensing partnership

Ferring Pharmaceuticals and PharmaBiome announced a comprehensive research and development collaboration today.

Study reveals the microbiota of people with genetic immune deficiency

A recent study analyzed microbial colonization in people with RAG deficiency to shed light on the effects of secondary immunodeficiencies.

Linking gut microbiota diversity to survival outcomes in children’s stem cell transplants

Results from a recent study suggest a correlation between the diversity and composition of the gut microbiota prior to transplantation and both the patient's survival and the probability of developing…

Mixture of milk sugars and live bacteria may restore damaged gut microbiotas

The findings of a recent study suggest that a mixture of B. infantis and HMOs can modulate the gut microbiota in adults.

Dietary intervention may change the microbiota, alleviate fatty liver disease

The findings of a recent study suggest that resistant-starch supplements can alter the gut microbiota in ways that alleviate NAFLD.

How physical activities shape our gut microbiome

Silvia Barbaresi, molecular biologist, researcher and nutritionist at Ghent Univerity, discusses how sports and physical activity in general impact on gut microbiota composition.

Boehringer Ingelheim acquires T3 Pharma, boosting immuno-oncology efforts

In a significant move to expand its immuno-oncology portfolio, Boehringer Ingelheim has acquired T3 Pharmaceuticals AG, a Swiss biotech company specializing in bacterial cancer therapy.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Scroll to Top